NewAmsterdam Pharma Company N.V. (NAMS)
- Previous Close
18.82 - Open
19.17 - Bid 19.27 x 300
- Ask 19.44 x 200
- Day's Range
18.46 - 19.62 - 52 Week Range
5.63 - 26.35 - Volume
235,796 - Avg. Volume
173,295 - Market Cap (intraday)
1.747B - Beta (5Y Monthly) 0.08
- PE Ratio (TTM)
-- - EPS (TTM)
-2.70 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
34.71
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
www.newamsterdampharma.comRecent News: NAMS
Performance Overview: NAMS
Trailing total returns as of 5/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NAMS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NAMS
Valuation Measures
Market Cap
1.69B
Enterprise Value
1.21B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
229.97
Price/Book (mrq)
4.11
Enterprise Value/Revenue
176.69
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-24.82%
Return on Equity (ttm)
-54.33%
Revenue (ttm)
6.86M
Net Income Avi to Common (ttm)
-228.69M
Diluted EPS (ttm)
-2.70
Balance Sheet and Cash Flow
Total Cash (mrq)
481.15M
Total Debt/Equity (mrq)
0.01%
Levered Free Cash Flow (ttm)
-82.2M